News
Article
Author(s):
Congruence secures a $5 million grant to advance innovative therapies for GBA1 Parkinson's disease, enhancing hope for patients and research breakthroughs.
Congruence announced it received a $5 million research grant from the Michael J. Fox Foundation.
stock.adobe.com
Congruence announced it received a $5 million research grant from the Michael J. Fox Foundation for Parkinsons research. The computationally driven biotechnology company is known for its pipeline of correctors for diseases of protein misfolding, including MC4R deficient genetic obesity, GBA-driven Parkinson’s disease, and Alpha-1 antitrypsin deficiency.
Dr. Clarissa Desjardins, CEO of Congruence, commented on the grant, saying, "We are honored to receive this grant from The Michael J. Fox Foundation. Their confidence strengthens our commitment to apply Congruence's computational drug discovery tools toward the development of GCase-targeting therapies that bring hope to the Parkinson's community." 1
The largest genetic risk of Parkinson’s disease is mutations of the GBA1 gene encoding the GCase enzyme. Attempting to treat these mutations, Congruence employed the use of its advanced computational engine Revenir to discover and examine small molecules designed to correct biological deficits of GBA1 gene mutations. In specific GBA1 Parkinson’s disease, GCase deficiency is correlated with the accumulation of a-synuclein alongside the death of neuronal cells, which are the hallmarks of Parkinson’s.
With no current disease-modifying therapies available, Congruence anticipates the new research grant will accelerate research methods for GBA1 Parkinson’s treatment through lead optimization towards the clinic.
The 2025 GBA1 meeting was supported by The Michael J. Fox Foundation and consisted of stakeholders in academia alongside GBA1 specialized industry members. It was here that Congruence scientists conducted an oral presentation on the discovery of potent orally active and brain penetrant allosteric GCase activator and corrector molecules for clinical evaluations in Parkinsons disease.1
Sharath Hegde, Ph.D., chief scientific officer of Congruence touched on the opportunity to present at the meeting saying, "We are pleased to present our science on novel GCase activators and correctors for GBA1 Parkinson's Disease at this important scientific congress, we are developing small molecules discovered leveraging our Revenir™ platform that are designed to correct biological deficits resulting from mutations in the GBA1 gene. We look forward to advancing the most potent orally active and brain-penetrant allosteric GCase activator and corrector molecules for future evaluation in people living with Parkinson's disease." 2
With its new $5 million grant, Congruence’s continued efforts in research and development of GBA1 Parkinson’s disease therapies receives its deserved recognition, with Michael J. Fox Foundation chief scientist Brian Fiske, PhD saying, "The Michael J. Fox Foundation supports a broad portfolio of research and drug development around important Parkinson's disease biology such as GBA1. Congruence's efforts to advance novel therapies contribute critically to our shared commitment to deliver new treatments for people with Parkinson's."1
Congruence’s pipeline of self-owned drugs for high-value genetically validated difficult-to-drug targets is anticipated to benefit from the $5 million grant, with genetic obesity and a1-Antitrypsin deficiency treatments being included alongside GBA Parkinson’s disease treatments. Pairing the grant with Congruence’s new collaborations for multi-target research focused on small molecule correctors for tumor and metabolic disease treatments, Congruence is striving to advance the future of GBA Parkinson’s disease research.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
